新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 帕金森病 » 检测血液脑蛋白含量诊断帕金森氏病的新技术

检测血液脑蛋白含量诊断帕金森氏病的新技术

来源:生物谷 2007-05-08 09:12

    澳洲科学家已研发出世界第一种帕金森氏病诊断法,可以在症状开始出现前,就能诊断出这种疾病。

    墨尔本的研究人员希望他们研发出的血液样品检测技术,不久后可以能成为第一种准确诊断出帕金森氏病的方法。他们希望这种检测血液脑蛋白含量的技术,今后有一天能用来预测每位病人的病状发展情况。

    Howard Florey研究所的神经科学家Malcolm Horne表示,它目前仍处于早期阶段,但这种技术有助于研究人员更了解这种疾病。

    Horne教授和其它墨尔本大学的研究人员发现,那些脑神经功能退化的患者,通常血液中一种脑分泌的Alpha-Synuclein蛋白质含量高于身体健康的人。Alpha-Synuclein蛋白是一种神经元特异性突触前膜蛋白,也是Lewy小体的重要组成分。近年研究认为,Alpha-Synuclein与帕金森病的关系密切。这项发现显示,即使这种蛋白质不是造成帕金森氏病的原因,也与帕金森氏病有重要的关连性。据统计,帕金森氏病影响八万名澳洲人。

    (编译/姜欣慧) (资料来源 : Bio.com)

英文原文:

New Blood Test can Diagnose and Monitor Treatment of Parkinson's Disease

04/26/07 -- While Florey researchers have also created a genetic test for PD (10% of PD cases are caused by genetic factors), this new test has a broader application by screening for many different types of PD and monitoring treatment, as well as measuring the effectiveness of drugs being developed to treat the disease.

Dr Qiao-Xin Li and colleagues from The University of Melbourne and The Mental Health Research Institute of Victoria, along with Prof Malcolm Horne from the Howard Florey Institute, found people with PD had low levels of the brain-secreted protein 'alpha-synuclein' in their blood, while people without PD had high levels of the protein.

Prof Horne said the test they developed measured alpha-synuclein levels in blood.

"Currently there is no specific PD diagnostic test so doctors rely on their observations to make a diagnosis, which means some patients may not be prescribed the most suitable medication and around 15% of those diagnosed may actually be suffering from something else," Prof Horne said.

"Further studies are required to establish whether this test can distinguish between people who are responsive to treatment and those who are not," he said.

The researchers are now conducting a large-scale study to determine the effectiveness of the test, to discover whether it is applicable for all types of PD, and to find out if it can measure the rate of progression and severity of the disease.

"If the results of our large-scale study are encouraging, this test could be available for clinical use within the next two years," Prof Horne said.

"We are now refining the test to make it quicker and cheaper so it can be offered to all those who have or are at risk of developing PD.

"While the clinical outcomes for this test will be significant, it also opens up new avenues of PD research and drug development.

"Further research using this test will also help us better understand the many different forms of PD and work towards ways to prevent or delay the disease.

"The test will also ensure drug trial participants actually have PD so research outcomes will be statistically more valid, which paves the way for faster and more effective drug development.

"When drugs that modify disease progression are available, this test may also help in showing whether candidate drugs are having an effect on the disease by keeping alpha-synuclein levels close to normal," Prof Horne said.

Source: Research Australia

相关报道:

德国已成功利用超声波诊断帕金森氏症

Lancet:沿用20多年的中国人帕金森患病率 作出重大修正

抗帕金森病新药在我国上市

首批帕金森模式动物问世

脑起搏器开辟帕金森病治疗新途径

帕金森氏症遗传背景研究新进展

英专家称帕金森氏症也威胁年轻人

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库